diabetes-congress-2019-scientifictracks

3 / 7

Diabetes Congress 2019 Journal of Diabetology | Volume 3
Page 12
June 24-25, 2019 | Philadelphia, USA
DIABETES, ENDOCRINOLOGY, NUTRITION
AND NURSING MANAGEMENT
2nd International Conference on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
GLUCOSE TOXICITY: THE WORLDWIDE PROBLEM AND THE ALL-NATURAL SOLUTION
John Burd
Founder & CEO of Lysulin, USA
Glucose is an essential ingredient in our diet and we all need it to produce the energy for everyday living.
And while glucose is essential, too much glucose over too long of a time is toxic to our bodies. Glucose tox-
icity leads to the development of Type 2 diabetes in both children and adults, demanding that our healthcare
systems spend a huge amount on treating diabetes and its complications. Chronic hyperglycemia leads to in-
sulin resistance. Insulin is the hormone needed for glucose to enter our cells to produce energy. Need to make
insulin in an attempt to lower blood sugar can in turn lead to an inability to make insulin. When this happen
as in the case of Type 2 diabetes, author may have to resort to injection of insulin in order to try to keep our
blood glucose levels in the normal range. Glucose is not a passive bystander in our bloodstream but is a toxic
and reactive compound. Glucose reacts with all of the proteins in our body forming glycated proteins. These
glycated proteins progress to become what is known as advanced glycation end products or AGEs. These AGEs
are known to be the culprits in many disease complications including cardiovascular disease. Protein glycation
may also be the cause of insulin resistance. If insulin and/or the insulin receptors on cells become glycated,
this changes their ability to effectively function. This is one hypothesis on the mechanism of insulin resistance.
There is now an all-natural solution to the glucose toxicity problem. In over 20 years of R& D and clinical
studies, nutritional supplements have been proven to combat glucose toxicity. Three important supplements
having this ability are the amino acid LYSINE, the mineral zinc and a vitamin, vitamin C. Combining these three
important supplements into one tablet makes a powerful weapon to combat glucose toxicity and protein gly-
cation. This weapon is Lysulin®. Current therapy for type 2 diabetes and the history of studies proving the
effectiveness of nutritional supplements will be presented along with recent data from double blind placebo
controlled studies with Lysulin.
John Burd is Founder and CEO of Lysulin Inc., developing scientifically proven nutraceutical products to improve the health of peo-
ple with diabetes. The first patent pending product, Lysulin®, was launched in January 2018 and is showing remarkable results in
clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. He was also the co-founder of Sabur
Technology Inc., developing a new non-invasive continuous glucose monitoring technology. Prior to Sabur, he was Founder and
CEO of Oculir Inc., a general partner of Windamere Venture Partners; Chairman & CEO of MiraMedica, a company developing com-
puter-aided detection technology for enhanced cancer diagnosis. MiraMedica was sold to Kodak in August 2003. In 2010, he was
inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical
chemistry.
BIOGRAPHY
John Burd, J Diabetol 2019, Volume 3